Join us for an in-depth exploration of the most impactful developments presented at the EULAR 2025 Congress, focusing specifically on Systemic Lupus Erythematosus and Lupus Nephritis.

We break down the key takeaways, including:

- New insights into hydroxychloroquine monitoring and glucocorticoid tapering guidance

- "LAMDA," a novel scoring system for lupus arthritis

- Breakthroughs in LN treatment, including the REGENCY trial for obinutuzumab and combinations with existing therapies.

- Updated perspectives on belimumab and anifrolumab, exciting novel therapies in development, and the future of cellular therapies for severe lupus.

Disclaimer: During Lupus Academy podcast episodes, participants may refer to off-label use of medicines for patients with lupus. Lupus Academy does not make anyrecommendations about using a medicine outside the terms of its approved license for use.

Dr Raquel Faria and Professor David Isenberg review selected highlights from the 16th International Congress on SLE. Join us for a groundbreaking discussion on the latest inlupus research, clinical trials, guidelines and patient reported outcomes.

Disclaimer: During Lupus Academy podcast episodes, participants may refer to off-label use of medicines for patients with lupus. Lupus Academy does not make anyrecommendations about using a medicine outside the terms of its approved license for use.

Dr Raquel Faria and Professor David Isenberg discuss the impact of neurological events in SLE including their associated mortality risk, effect on patients’ QoL, fatigue and persistent neurological impairment throughout life.

Disclaimer: During Lupus Academy podcast episodes, participants may refer to off-label use of medicines for patients with lupus. Lupus Academy does not make anyrecommendations about using a medicine outside the terms of its approved license for use.

In this episode, Dr. Raquel Faria hosts a discussion with Professors David Isenberg and Murray Urowitz from the Lupus Academy Steering Committee. They delve into two historic cases: one involving Lupus and Myocardial Infarction, and the other focusing on Lupus Nephritis.

Disclaimer: During Lupus Academy podcast episodes, participants may refer to off-label use of medicines for patients with lupus. Lupus Academy does not make anyrecommendations about using a medicine outside the terms of its approved license for use.

In this episode, Dr Raquel Faria discusses a complex case with Professors Andrea Doria and Maria Dall’Era of the Lupus Academy Steering Committee.

 Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines forpatients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.

Join Dr Raquel Faria and Professors Richard Furie and Maria Dall’Era as they discuss the results of the phase 3 REGENCY trial of obinutuzumab for the treatment of lupus nephritis.This episode explores what obinutuzumab could mean for the future management of lupus nephritis.

Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines forpatients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.

 Join Dr Raquel Faria and Professors David Isenberg and Ronald van Vollenhoven as they discuss the groundbreaking

In this episode our host Dr Raquel Faria discusses the challenges in the management of lupus in low to middle income countries with Professor Sandra Navarra of the Lupus Academy Steering Committee.

For Prof Sandra Navarra's presentation, please refer to the free access Lupus Academy Online Library.

Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines for

In this episode our host Dr Raquel Faria covers key

Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines for

In this episode our host Dr Raquel Faria discusses two intriguing cases from the clinic with Professors Ronald van Vollenhoven and Zahir Amoura of the Lupus Academy Steering Committee.

Case 1: 32-year-old female with severe neutropenia

Case 2: 26-year-old female with Diffuse Alveolar